Drug Profile
ASN 009
Alternative Names: ASN009Latest Information Update: 28 Sep 2022
Price :
$50
*
At a glance
- Originator Asana BioSciences
- Class Analgesics; Anti-inflammatories; Urologics
- Mechanism of Action Purinergic P2X3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cough; Pruritus
- No development reported Genitourinary disorders; Pain
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for preclinical development in Genitourinary-disorders in USA (PO)
- 28 Sep 2022 No recent reports of development identified for preclinical development in Pain in USA (PO)
- 08 Sep 2020 ASN 009 is still in preclinical trials for Genitourinary disorders and Pain in USA (Asana BioSciences pipeline, September 2020)